Leader Medicated Relief Patch

Camphor (synthetic) Levomenthol Salicylic Acid


Cardinal Health, Inc
Human Otc Drug
NDC 70000-0206
Leader Medicated Relief Patch also known as Camphor (synthetic) Levomenthol Salicylic Acid is a human otc drug labeled by 'Cardinal Health, Inc'. National Drug Code (NDC) number for Leader Medicated Relief Patch is 70000-0206. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Leader Medicated Relief Patch drug includes Camphor (synthetic) - 1.2 1/1 Levomenthol - 5.7 1/1 Methyl Salicylate - 6.3 1/1 . The currest status of Leader Medicated Relief Patch drug is Active.

Drug Information:

Drug NDC: 70000-0206
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Leader Medicated Relief Patch
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Camphor (synthetic) Levomenthol Salicylic Acid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Cardinal Health, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Patch
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAMPHOR (SYNTHETIC) - 1.2 1/1
LEVOMENTHOL - 5.7 1/1
METHYL SALICYLATE - 6.3 1/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Dec, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 14 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:CARDINAL HEALTH, INC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:853260
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:5TJD82A1ET
BZ1R15MTK7
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
70000-0206-120 POUCH in 1 BOX (70000-0206-1) / 1 PATCH in 1 POUCH01 Dec, 2016N/ANo
70000-0206-240 POUCH in 1 BOX (70000-0206-2) / 1 PATCH in 1 POUCH01 Dec, 2016N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical analgesic

Product Elements:

Leader medicated relief patch camphor (synthetic) levomenthol salicylic acid glycerin styrene hydrated silica mineral oil polyisobutylene (1100000 mw) polyethylene glycol 400 zinc oxide natural latex rubber camphor (synthetic) camphor (synthetic) levomenthol levomenthol methyl salicylate salicylic acid

Indications and Usage:

Indications & usage temporary relief of aches and pains associated with arthritis, simple backache, strains, sprains, bruises.

Warnings:

Warnings for external use only

Do Not Use:

Warnings for external use only

When Using:

When using this product: use only as directed avoid contact with eyes, mucous membranes or skin rashes.

Dosage and Administration:

Dosage & administration adults and children over 12 years: clean and dry affected area. carefully remove backing from patch. apply sticky side of patch to affected area. wear one patch up to 8 hours. repeat as necessary, no more than 4 times daily, no more than 7 consecutive days. children 12 years or younger, consult a physician.

Stop Use:

Top use and consult a doctor if rash, itching or excessive skin irritation develops if condition worsens if symptoms last more than 7 days or clear up and occur again.

Package Label Principal Display Panel:

Medicated relief label image


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.